Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
1. Clear MoA:
(1) HER2 is overexpressed or mutated in 25% of breast cancer patients, according to TCGA data. Herceptin, a HER2 mAb, targeting HER2 overexpressing cancers have proven to be beneficial. However, approximately 70% of patients develop resistance to Herceptin, and some patients present with primary resistance, who are seeking for an after-Herceptin solution.
(2) The resistance of immunotherapy in HER2+ breast cancer occurs because of the formation of immunosuppressive TME primarily or secondarily. Her2xCD3 BsAb is an ideal strategy to overcome the immunosuppressive TME barrier.
(3) Her2xCD3 BsAb redirect T cells to target HER2-expressing tumor cells and to eradicate HER2+ cancer cells. The advantage of the BsAb strategy is that T cell activation is independent of antigen specificity, and a large fraction of the T cells are activated.
2. Excellent pre-clinical result:
(1) This asset could bind to HER2 and CD3 simultaneously.
(2) Excellent safety and efficacy. 1) induces lower ADCC on HER2+ tumor cells and has no cytotoxic on CD3+ Jurkat Cell, comparing with anti-HER2 or anti-CD3 antibody, respectively. 2) able to kill HER2+ tumor cell lines and has little effect in HER2- tumor cell line. 3) dose-dependent induced IL-6 and TNFa in day 1 treatment, and no cytokine release was detected in the longer 72 days treatment in cyno monkey. 4) showed dose-dependent anti HER2+ tumor efficacy in vivo.
3. Excellent clinical result:
Good tolerance and effective in anti-HER2 resistance patients in phase 1 study. 1) All the patients were refractory or relapsed from multiple lines of anti-HER2 treatment. 2) No patients experienced DLT. Only 1 out of 7 patients experienced Gr1 CRS and no CRS occurred after priming dose; 3) No neurotoxicity and immune suppression were observed during the DLT period, much safer than ADC; 4) DCR@100 ug cohort = 66% (n=3); 1 PD, 2 SDs.
1. Asset type: Her2xCD3 BsAb
2. Indication: HER2+ Cancer
3. Research phase: Phase I
4. Cooperation demands: License-out and co-development
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
This web search service is supported by Google Inc.
A-Z
